Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
March 31 2017 - 4:01PM
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers for patient enrichment,
today announced that it has been added to the Russell 2000®, 3000®
and Microcap® Indexes, effective March 31, 2017, as part of
Russell’s quarterly additions of companies with recent initial
public offerings.
The Russell 2000® Index measures the performance of
the small-cap segment of the U.S. equity market and is a subset of
the Russell 3000®, representing approximately 10 percent
of the total market capitalization of that index. Membership in
the Russell 2000® Index includes automatic inclusion in
the appropriate growth and style indexes. The Russell
Microcap® Index represents 2,000 small cap and micro-cap stocks
that captures the smallest 1,000 companies in the Russell 2000®, in
addition to 1,000 smaller U.S.- based listed stocks.
Russell indices are widely used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies. Russell Investments
determines membership for each index based on objective market
capitalization rankings and style attributes.
About Jounce Therapeutics Jounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long‑lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right therapy to the right patient. Jounce’s
lead product candidate, JTX-2011, is a monoclonal antibody that
binds to and activates ICOS and is currently in a Phase 1/2 trial.
For more information, please visit http://jouncetx.com/
Media Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024